Featured Publications
Cancer Immunoediting in the Era of Immuno-oncology.
Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research 2022, 28: 3917-3928. PMID: 35594163, PMCID: PMC9481657, DOI: 10.1158/1078-0432.ccr-21-1804.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCancer immunoeditingImmune-tumor cell interactionsCancer immunotherapyAbsence of immunotherapyDurable clinical responsesT cell biologyCell interactionsImmunotherapy resistanceClinical responseImmunosuppressive microenvironmentTumor immunogenicityImmuno-oncologyClinical dataPreclinical modelsImmunoeditingImmunotherapyHuman patientsImmune systemTumor microenvironmentCancerCancer progressionClinical subspecialtyImmunogenicityMicroenvironmentPatientsClinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
Noelle R, Lines J, Lewis L, Martell R, Guillaudeux T, Lee S, Mahoney K, Vesely M, Boyd-Kirkup J, Nambiar D, Scott A. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers In Oncology 2023, 13: 1225081. PMID: 37795437, PMCID: PMC10547146, DOI: 10.3389/fonc.2023.1225081.Commentaries, Editorials and LettersImmune checkpoint proteinsImmune checkpointsImmune systemT-lymphocyte antigen-4Cell death protein 1V-domain immunoglobulin suppressorDeath protein 1CD28 family membersAnti-VISTA antibodyT cell activationImportant homeostatic functionsVISTA blockadePD-1Proinflammatory changesImmune effectsMyeloid suppressionAntigen-4CTLA-4Immune cellsT cellsImmune responsePreclinical studiesClinical developmentHomeostatic functionsMyeloid lineageNormalization Cancer Immunotherapy for Melanoma
Vesely MD, Chen L. Normalization Cancer Immunotherapy for Melanoma. Journal Of Investigative Dermatology 2020, 140: 1134-1142. PMID: 32092349, PMCID: PMC7247948, DOI: 10.1016/j.jid.2020.02.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNormalization cancer immunotherapyCancer immunotherapyImmune responseDysfunctional immune responseSystemic immune responsesContext of melanomaPatient survivalTreatment of cancerTumor responseImmunotherapyToxicity profileImmune systemTumor microenvironmentMelanomaCancerDistinct mechanismsResponseCliniciansNatural Innate and Adaptive Immunity to Cancer
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive Immunity to Cancer. Annual Review Of Immunology 2011, 29: 235-271. PMID: 21219185, DOI: 10.1146/annurev-immunol-031210-101324.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune systemAdaptive immune cell typesImmune cell typesTumor-promoting actionsHuman clinical dataNascent tumor cellsCancer immunosurveillanceClinical dataAdaptive immunityMouse modelTumor progressionCancerTumor cellsTumor suppressor mechanismImmunityEffector moleculesFurther studiesCell typesCompelling evidenceImportant defenseImmunotherapyImmunosurveillanceInnateProgression
2020
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.
Vesely MD. Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. The Yale Journal Of Biology And Medicine 2020, 93: 197-206. PMID: 32226348, PMCID: PMC7087062.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous autoimmune diseasesAutoimmune diseasesCutaneous autoimmunityImmune systemEffector armT cellsTherapeutic strategiesChimeric autoantibody receptor T cellsRegulatory armLow-dose interleukin-2Regulatory T cellsExcessive immune activationReceptor T cellsGreater treatment efficacyBroad immunosuppressantsCytokine blockadeTolerogenic vaccinesCostimulatory blockadeDisease remissionImmune activationInflammatory pathwaysImmune homeostasisInterleukin-2Treatment efficacyNormal skin
2013
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals Of The New York Academy Of Sciences 2013, 1284: 1-5. PMID: 23651186, PMCID: PMC3648872, DOI: 10.1111/nyas.12105.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune systemTumor-specific antigensHuman cancer patientsTumor-promoting actionsNascent tumor cellsAntitumor immunityTumor immunityCancer immunosurveillanceChronic inflammationPersonalized cancer therapyImmunogenic variantsCancer immunotherapyCancer patientsCancer immunoeditingT cellsAnimal modelsTumor variantsTumor progressionTumor cellsCancer cellsImmunityCancer therapyCancerAntigenImmunoselection
2012
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research 2012, 72: 3987-3996. PMID: 22869585, PMCID: PMC4384890, DOI: 10.1158/0008-5472.can-12-1337.Peer-Reviewed Original ResearchConceptsIL-12IL-23Antibody treatmentImmune systemCD40 antibody treatmentIL‐12/23p40 antibodiesAutoimmune inflammatory disorderMonoclonal antibody treatmentOccult neoplasiaOccult cancerIL-17IL-23p19IL-12/23p40Immune controlInflammatory disordersTumor immunogenicityIL-4Malignant potentialCancer immunoeditingTumor outgrowthElimination phaseTumor growthTumor dormancyMutant cancersCancer cells